Safety Monitoring of Medicinal Products: Guidelines for Setting Up and Running a Pharmacovigilance Centre
(2000; 28 pages) [French]
Table des matières
Afficher le documentINTRODUCTION
Afficher le document1. WHY PHARMACOVIGILANCE?
Afficher le document2. DEFINITION AND AIMS
Ouvrir ce répertoire et afficher son contenu3. HOW TO START A PHARMACOVIGILANCE CENTRE
Ouvrir ce répertoire et afficher son contenu4. REPORTING OF ADVERSE DRUG REACTIONS
Fermer ce répertoire5. SPECIAL ISSUES IN REPORTING
Afficher le document5.1 Central or decentralised reporting?
Afficher le document5.2 Stimulation of reporting
Afficher le document5.3 Under-reporting
Ouvrir ce répertoire et afficher son contenu6. PRACTICALITIES IN THE ORGANISATION OF A PHARMACOVIGILANCE CENTRE
Ouvrir ce répertoire et afficher son contenu7. ASSESSMENT OF CASE REPORTS
Ouvrir ce répertoire et afficher son contenu8. USE OF THE DATA
Ouvrir ce répertoire et afficher son contenu9. RELATIONS WITH OTHER PARTIES
Afficher le document10. OTHER SOURCES OF INFORMATION
Afficher le document11. FUNDING
Afficher le documentREFERENCES
Afficher le documentGLOSSARY
Afficher le documentCAUSALITY CATEGORIES
Afficher le documentWHO CONTACTS
 

5.2 Stimulation of reporting

The reporting of adverse reactions needs continuous stimulation. It is important to achieve the development of a positive attitude towards pharmacovigilance among healthcare professionals so that adverse reaction reporting becomes an accepted and understood routine. In summary, the following may stimulate reporting:

• easy access to pre-paid reporting forms and other means of reporting

• acknowledging the receipt of adverse drug reaction reports by personal letter or phone call

• providing feedback to reporters in the form of articles in journals, adverse drug reaction bulletins or newsletters

• participation of the centres staff in pre- and postgraduate education and scientific meetings

• collaboration with local drug or pharmacovigilance committees

• collaboration with professional associations

• integration of pharmacovigilance in the (further) development of clinical pharmacy and clinical pharmacology in a country.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013